Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings

The aim of this study was to evaluate the clinical efficacy as determined by time to progression and response rate (RR) of autologous vitespen (formerly HSPPC-96; Oncophage, Antigenics Inc., New York, NY, USA) with and without interleukin-2 (IL-2; Proleukin: Chiron, Emoryville, CA, USA) in stage IV...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonasch, E, Wood, C, Tamboli, P, Pagliaro, L C, Tu, S M, Kim, J, Srivastava, P, Perez, C, Isakov, L, Tannir, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361701/
https://www.ncbi.nlm.nih.gov/pubmed/18362942
http://dx.doi.org/10.1038/sj.bjc.6604266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361701/
https://www.ncbi.nlm.nih.gov/pubmed/18362942
http://dx.doi.org/10.1038/sj.bjc.6604266

Ejemplares similares